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Abstract
Background: Limited evidence suggests that dietary interventions may offer a promising approach for migraine.
The purpose of this study was to determine the effects of a low-fat plant-based diet intervention on migraine
severity and frequency.
Methods: Forty-two adult migraine sufferers were recruited from the general community in Washington, DC, and
divided randomly into two groups. This 36-week crossover study included two treatments: dietary instruction and
placebo supplement. Each treatment period was 16 weeks, with a 4-week washout between. During the diet period,
a low-fat vegan diet was prescribed for 4 weeks, after which an elimination diet was used. Participants were
assessed at the beginning, midpoint, and end of each period. Significance was determined using student’s t-tests.
Results: Worst headache pain in last 2 weeks, as measured by visual analog scale, was initially 6.4/10 cm (SD
2.1 cm), and declined 2.1 cm during the diet period and 0.7 cm during the supplement period (p=0.03). Average
headache intensity (0–10 scale) was initially 4.2 (SD 1.4) per week, and this declined by 1.0 during the diet period
and by 0.5 during the supplement period (p=0.20). Average headache frequency was initially 2.3 (SD 1.8) per week,
and this declined by 0.3 during the diet period and by 0.4 during the supplement period (p=0.61). The Patient’s
Global Impression of Change showed greater improvement in pain during the diet period (p<0.001).
Conclusions: These results suggest that a nutritional approach may be a useful part of migraine treatment, but that
methodologic issues necessitate further research.
Trial registration: Clinicaltrials.gov, NCT01699009 and NCT01547494.
Keywords: Migraine; Headache; Nutrition; Diet; Plant-based; Vegan
Background
Migraine disorder is characterized by headaches with
moderate to severe pain, often having a unilateral loca-
tion and pulsating quality, accompanied by nausea,
vomiting, photophobia, or phonophobia [1]. Migraines
affect over 28 million Americans and occur at all ages,
more often in women than men [2]. Medications have
an important role in prevention and treatment but are
limited in effectiveness while carrying side effects that
may include cardiovascular risks and headaches due to
medication overuse. The pathology of migraine is in-
completely understood, but evidence suggests dietary
factors may contribute, perhaps through inflammation
and vasodilation.
Limited evidence suggests that dietary interventions
may offer a promising approach for migraine [3]. A low-
fat diet has been shown to reduce headache frequency,
intensity, and duration, with subsequently lowered medi-
cation use [4]. A recent review identified 16 population
studies with data on dietary precipitating factors [5].
Greater than 5% of participants identified specific food
triggers in 8 of the studies. The most commonly re-
ported triggers in these and other analyses include: choc-
olate, cheese, citrus, alcohol, and coffee [5,6]. In these
articles, triggers were reported retrospectively by pa-
tients, but other studies have identified triggers via elim-
ination diets [7].
Some have attempted to identify dietary triggers via
blood testing for IgG antibodies. In a small randomized
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cross-over study, participants’ blood was tested for anti-
bodies against 266 foods. Each participant eliminated
foods for which they had antibodies, leading to a 29% re-
duction in migraine days [8]. A subsequent randomized
controlled trial eliminated antibody-promoting foods in
the diets of 84 migraineurs [9]. After 4 weeks, this diet
was associated with a 19% reduction in headache days as
compared with the control “sham” diet. While similar
antibody tests do not show predictive value for other in-
dications [10,11], these studies demonstrate the potential
of food elimination for reducing pain.
Diet may also affect migraines through more indirect
mechanisms. Changes in plasma estrogen concentrations
throughout menstrual cycles are strongly associated with
migraine [12]. Diet changes, particularly a low-fat, high-
fiber, vegan diet, appear to reduce estrogen activity and the
intensity and duration of premenstrual symptoms [13].
Therefore, such a diet may be expected to reduce frequency
of headaches occurring in the premenstrual period.
These data suggest that a low-fat, vegan diet may be
beneficial, combining the advantages of a high-fiber diet
and a diet free of animal-derived triggers. To our know-
ledge, vegan diets have not been tested for therapeutic
potential in migraine. We hypothesized that a vegan
dietary intervention designed to eliminate potential diet-




Individuals with recurrent migraine were recruited from
the Washington, DC, area through newspaper and radio
advertisements and a letter from a local neurologist. All
participants had a prior migraine diagnosis, as defined by
the criteria of the second edition of the International Clas-
sification of Headache Disorders, [1] experienced migraines
at least twice per month, were over 18 years of age, and
were following an omnivorous or lacto-ovo vegetarian diet.
The study was approved by Ethical and Independent Re-
view Services. A screening interview was conducted to de-
termine eligibility. All participants gave informed consent.
No inducements for participation were provided. The
study was registered at clinicaltrials.gov with registration
numbers NCT01699009 and NCT01547494.
Volunteers were randomly assigned by study staff, using
a random-number table, to group 1 or 2 for 36 weeks. Allo-
cation concealment was achieved using unmarked assign-
ment envelopes. It was not possible to blind participants
and instructors to group assignment.
Study design and procedures
We used a crossover design to compare a diet change
with a placebo supplement. Participants were randomly
assigned either (1) to make dietary changes or (2) to take
a placebo supplement and make no diet changes for the
first 16 weeks of the study. After a 4-week washout
period with no treatment, participants crossed over to
the other treatment condition for the last 16 weeks of
the study (Figure 1). During the diet period, participants
received weekly dietary instruction. A low-fat vegan diet
was prescribed for 4 weeks, after which an elimination
diet was used to enable participants to identify possible
specific pain trigger foods. During the elimination diet
period, participants were asked to continue the low-fat
vegan diet and also to eliminate common trigger foods,
chosen based on previous studies (Table 1) [2,6,14]. Par-
ticipants were asked to adhere to the elimination diet
until no further improvement was noted or until the
period midpoint (typically 10–21 days), after which they
were asked to reintroduce the omitted foods one at a
time, starting with foods least likely to be a trigger, every
48 hours and report subsequent headaches.
The placebo supplement was a capsule containing 10
mcg alpha-linolenic acid and 10 mcg vitamin E, packaged
in a plain white bottle. This supplement was chosen be-
cause it could credibly be presented as potentially having
some clinical efficacy, while having no actual effect in the
current study. In higher doses, omega-3 oils and vitamin E
may have efficacy in inflammatory conditions [15,16]. The
participants were told that the supplement contained a
mixture of omega-3 oils and vitamin E. Participants were
asked to take one capsule daily.
Participants were asked to keep their medications con-
stant to the extent possible, but to follow the advice of
their personal physicians.
Dependent variables
Our primary outcomes were headache frequency as
measured by headache diaries and pain severity as mea-
sured by a physician-administered visual analog scale
(VAS). Assessments occurred at the beginning, mid-
point, and end of each 16-week period. To monitor diet-
ary intake, participants completed 2-day diet records
and filled out a diet questionnaire that included ques-
tions about avoiding foods and consumption frequency.
Figure 1 Study design. Group 1 did the diet treatment first,
followed by the supplement treatment. Group 2 did the two
treatments in the reverse order.
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Two-day diet records are a valid means of measuring
food and nutrient intakes [17]. Body weight, body mass
index (BMI, weight in kilograms divided by height
squared), and plasma lipid concentrations were also
assessed. Participants rated headache pain using a visual
analog scale. Participants were asked to mark along a
10 cm line according to the severity of their worst head-
ache pain in the preceding 2 weeks. The scale was an-
chored on the left side with the words “No pain” and on
the right side with “Pain as bad as it could possibly be”.
At the end of each treatment period, patients were
asked to rate symptom change during that period using
an 5-point Likert-style scale, ranging from “much worse”
to “much better”. In the 2nd replication, this scale was
replaced by the patient’s global impression of change
(PGIC) question, which measures subjective pain im-
provement by asking participants to rate symptom
change on a scale of 1–7 from “no change” to “a great
deal better” [18]. This change was made to utilize a vali-
dated scale. Participants also kept a weekly diary of
headache number, intensity (numerical rating scale from
1 to 10), and duration during the entire study. Headache
frequency was defined as average number of headaches
per week. Multiple dimensions of wellness were assessed
with the Rand Short Form 36 (SF-36) [19].
Statistical analysis
Since little has been published on the effects of a vegan
diet on pain in migraine patients, a power analysis could
not be based on previous research. Therefore, we chose
an exploratory approach that did not limit sample size
and accepted all volunteers who met the inclusion
criteria.
For pain scales, body weight, and lipids (total choles-
terol, LDL-cholesterol, HDL-cholesterol, and triglycer-
ides), descriptive statistics were calculated. For normally
distributed data, parametric tests for significant effects
were used; for non-normally distributed variables, non-
parametric tests were used. An alpha of 0.05 was used
for all statistical tests. Headache diary data (headache
frequency, intensity, duration, and days) were averaged
over 4–8 weeks, based on the time between assessments.
For example, headache frequency was defined as the
average number of headaches per week since the last
assessment.
Two-tailed T-tests for independent samples were cal-
culated for the changes during the diet and supplement
periods (significance cutoff, 0.05). For the second 16-
week period, proximal baseline data (ie, data immedi-
ately preceding that period) were used, rather than
actual study baseline. For missing data, the most recent
available values were brought forward, except for body
weight, for which baseline values were used. For each
endpoint, 5-9% of datapoints were missing. Participants
who dropped out in the first period were deemed to
have had no change in any variable during the second
period. Both intention-to-treat analysis and completers
analyses were performed. For the completers analysis,
Table 1 Elimination diet






















Allium genus (onions, garlic) Vegetables:




Animal products (all)a Cabbage, Bok choy
Nuts and seeds (all) Carrots
Chocolate Greens: Chard, Kale, Collards,
Mustard, Spinach,
Sugar Lettuce









aParticipants avoided animal products during entire diet phase, not only
during elimination diet.
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only participants who attended the baseline and end-
point assessments for both treatments were included.
For the multivariate analysis, baseline values for key out-
come variables were included as covariates, regardless of
significant differences between the two groups at base-
line. Data analyses were performed by statisticians who
were impartial to the hypotheses being tested.
In addition, due to the complications associated with
the crossover design, a subanalysis of all variables was
performed on the first 16 weeks of data.
Results
Recruitment
Sixty-six participants were interviewed and 42 (mean
age 46 ± 13) were enrolled (Figure 2). Recruitment pe-
riods were December 2011-January 2012 and October
2012-January 2013. Participants were 93% women, well-
educated (95% college degree or higher), 83% white, and
90% non-Hispanic (Table 2). Among the 26 participants
reporting an onset date for their migraines, the mean
disease duration was 24 years. At baseline, 4 participants
met the criteria for chronic migraine (15 or more head-
ache days per month), while the rest met the criteria for
episodic. There were no significant demographic or clin-
ical differences between the groups. Thirty-eight partici-
pants (90%) completed the study (Figure 2). Most
participants reported following an omnivorous diet at
baseline, with 12% (N=5) following an ovo-lacto vegetar-
ian diet. None avoided all animal products at baseline.
There were no significant study-related adverse effects.
The study ended as per the protocol.
Diet adherence
On diet records conducted for 2 days at the diet inter-
vention period midpoint and again for 2 days at the end
of the diet period, 28 of the 42 participants reported no
consumption of animal products, while 7 reported con-
sumption of at least modest amounts of dairy products
or egg ingredients and 3 reported consumption of at
least modest amounts of meat during one of these diet-
record assessments. Diet adherence was not assessed for
the 4 drop-outs. Food frequency questionnaire data con-
firmed the findings of the diet records. Because the elim-
ination diet was individualized and participants were
free to implement it as they wished, it was not possible
to assess adherence to the elimination diet.
Changes on clinical measurements
In our intention-to-treat analysis, we combined data
from all participants for each period. Body weight fell by
3.6 kg during the diet period, and 0.1 kg during the sup-
plement period (p< 0.001, Table 3). Total cholesterol fell
by 14 mg/dL during the diet period, but increased by
1 mg/dL during the supplement period (p=0.03). LDL
cholesterol fell by 9 md/dL during the diet period, but
increased by 2 mg/dL during the supplement period
(p=0.04). For some variables, change scores showed
non-normality in at least one comparison group, but
non-parametric tests yielded results that did not mean-
ingfully differ from those of the parametric tests. The
completer analysis yielded essentially the same results as
the intention-to-treat analysis (Table 4).
Changes in reported pain
Severity of worst pain in the preceding 2 weeks, as mea-
sured by a visual analog scale, showed significantly more
improvement during the diet period than the supple-
ment period (−2.1 cm [35%] vs −0.7 cm [14%], p=0.030,
Table 3). Pain improvement as measured by the PGIC or
change in pain question was significantly greater after
the diet period, with 35 of 40 participants describing
their symptoms as “better” after the diet period, and 5
reporting no improvement, while participants were
evenly split after the supplement period, with 20 report-
ing improvement and 20 reporting no improvement
(p<0.001, Figure 3, Additional file 1: Table S1).
Non-parametric tests on non-normal data confirmed
the above results, except that decreases in number of
headaches (p=0.04) and number of medicated headaches
(p=0.004) were significant during the diet period (Table 3).
In a completers analysis, significant decreases in head-
ache intensity, duration, and percent headaches requir-
ing pain relief medication were observed during the diet
period (all p<0.01), and in headache number and days
during the supplement period (both p<0.03, Table 4). A
Figure 2 Recruitment and flow of participants through trial.
Study completers attended final assessment at 36 weeks. All enrolled
participants were included in the analysis.
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Table 2 Baseline characteristics
Variable All participantsa Group 1 (N=21) Group 2 (N=21) p valueb
Women N 39 19 (90%) 20 (95%) 0.55
College degree or higher N 40 20 (95%) 20 (95%) 0.32
White race N 35 18 (86%) 17 (81%) 0.68
Hispanic N 4 3 (14%) 1 (5%) 0.29
Nonvegetarian N 37 18 (86%) 19 (90%) 0.63
Mean (SD) Mean (SD) Mean (SD) p valuec
Age (y) 45.7 (12.7) 49 (13.5) 42.4 (11.1) 0.09
Weight (kg) 76.9 (19.8) 78.0 (22.6) 75.7 (17.1) 0.71
BMI 27.6 (6.0) 27.7 (6.4) 27.5 (5.8) 0.90
Illness duration (y) (N=26) 23.7 (12.6) 24.7 (13.8) 22.7 (11.7) 0.69
Total cholesterol (mg/dl) 191.1 (36.9) 195.6 (42.5) 186.9 (31.1) 0.46
VAS (cm) (N=41) 6.4 (2.1) 6.1 (2.4) 6.7 (1.9) 0.38
Headache number (per wk) (N=40) 2.3 (1.8) 2.1 (1.6) 2.6 (2.1) 0.50
Headache intensity, scale 0–10 (N=37) 4.2 (1.4) 3.9 (1.1) 4.5 (1.7) 0.20
Headache duration, hrs (N=38) 5.8 (3.4) 6.5 (3.3) 5.1 (3.5) 0.19
Headache days (per wk) (N=40) 2.2 (1.4) 2.1 (1.6) 2.3 (1.2) 0.64
Abbreviations: BMI Body Mass Index, VAS visual analog pain scale, worst pain last 2 weeks, SD standard deviation.
aN=42 unless otherwise indicated.
bP values from Chi squared tests for differences between groups.
cP values from Student’s T-tests for differences between groups.
Table 3 Diet effects on clinical measures, intention-to-treat analysis
Diet period Supplement period Effect
Sizee
p
valuefBaseline 16 weeks Change Baseline 16 weeks Change
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Body weight (kg) (N=42) 76.7 (20.2) 73.1 (19.4) −3.6 (3.8)a 74.9 (19.7) 74.8 (19.9) −0.1 (2.4) −3.5 (4.4) < 0.001
BMI (N=42) 27.5 (6.2) 26.2 (5.9) −1.3 (1.3)a 26.9 (6.0) 26.8 (6.1) 0.0 (0.9) −1.3 (1.6) < 0.001
Total cholesterol (N=41)g 189.5 (38.8) 175.8 (42.7) −13.7 (32.0)c 184.7 (33.6) 185.4 (38.0) 0.7 (26.2) −14.4 (40.5) 0.03
HDL (N=42) 61.1 (15.7) 55.3 (14.3) −5.8 (15.2)d 61.9 (14.1) 60.7 (14.3) −1.2 (10.0) −4.6 (19.0) 0.12
LDL (N=41) 108.8 (33.6) 99.8 (34.5) −9.0 (26.3)d 103.1 (28.3) 105.5 (32.7) 2.3 (22.7) −11.1 (33.6) 0.04
Ratio (N=41) 3.2 (0.9) 3.3 (0.9) 0.1 (0.8) 3.1 (0.7) 3.2 (0.8) 0.1 (0.7) −0.1 (1.2) 0.75
Triglycerides (N=41) 95.9 (44.3) 102.7 (42.1) 6.8 (51.9) 96.3 (35.1) 96.2 (51.7) −0.1 (49.2) 6.9 (77.6) 0.57
Log triglycerides (N=41) 1.94 (0.20) 1.98 (0.18) 0.04 (0.21) 1.96 (0.16) 1.94 (0.18) −0.01 (0.15) 0.05 (0.28) 0.25
VAS (cm) (N=41) 6.0 (2.7) 3.8 (3.0) −2.1 (3.2)b 4.9 (2.8) 4.2 (2.8) −0.7 (2.3) −1.4 (4.0) 0.03
Headache number (per wk) (N=40)h 2.1 (1.4) 1.8 (1.8) −0.3 (1.2) 2.2 (2.1) 1.8 (2.2) −0.4 (0.9) 0.1 (1.3) 0.61
Headache intensity (N=37) 4.3 (1.9) 3.3 (1.9) −1.0 (1.7)c 3.8 (2.0) 3.3 (2.0) −0.5 (1.5) −0.5 (2.5) 0.20
Headache duration, hrs (N=38) 6.2 (4.0) 5.2 (4.0) −0.9 (2.9) 5.2 (3.9) 4.8 (4.0) −0.3 (2.5) −0.6 (4.4) 0.44
Headache days (per wk) (N=40) 2.0 (1.4) 1.8 (1.5) −0.3 (1.1) 2.1 (1.7) 1.7 (1.6) −0.4 (0.8) 0.1 (1.3) 0.62
Medicated headache number (N=36) 1.4 (1.1) 1.1 (1.5) −0.2 (1.5) 1.4 (1.5) 1.1 (1.1) −0.3 (0.8) 0.0 (1.7) 0.90
% headaches medicated (N=36) 65.1 (33.5) 46.0 (32.7) −19.2 (39.3)c 52.6 (32.4) 49.4 (34.4) −3.2 (21.2) −16.0 (48.5) 0.04
Abbreviations: BMI Body Mass Index, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, Ratio= Total cholesterol/HDL, VAS visual
analog pain scale, worst pain last 2 weeks, SD standard deviation.
ap<0.0001, bp<0.001, cp<0.01, dp<0.05, all from within-group T-tests.
eEffect size is difference between diet treatment effect and supplement treatment effect.
fp value is from between group T-test.
gOne participant with incomplete blood lipids data was excluded from analyses of total, HDL, and LDL cholesterol and triglycerides. Cholesterol and triglycerides
are reported in mg/dl.
hVariable Ns reflect the fact that participants with incomplete headache diary data were excluded from analysis of headache number, intensity, duration, days,
and/or medication rates as appropriate.
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significant diet effect was observed for VAS (p=0.01) and
percent headaches medicated (p=0.02).
Differences in migraine prevention medication changes
were not significant. A subanalysis with only completers
who did not change their migraine prevention medica-
tions (N= 26) showed significant decreases in headache
intensity and the percent of headaches requiring pain re-
lief medication during the diet period as compared to
the control (both p<0.03).
Frequency of pain relief medication use fell by 19 ab-
solute percentage points (p=0.004) during the diet
period and 3 absolute percentage points during the sup-
plement period (Table 3). Headache intensity from diar-
ies declined by 1.0 point on a 0–10 scale during the diet
period, but only 0.5 points in the supplement period, al-
though this difference was not significant. The differ-
ences in the change scores for headache number,
intensity, duration, and days did not reach significance.
Changes in mood
In an intention-to-treat analysis, the SF-36 data showed
significant increases in social functioning (p=0.01) and
in physical functioning, role limitations due to physical
health, energy/fatigue, emotional well-being, pain, and gen-
eral health (all p<0.03), during the diet period, although
between-period differences did not reach statistical signifi-
cance (Additional file 1: Table S2). Pain rated on the SF-36
improved by 17 points in the diet period, but also improved
by 13 points in the supplement period.
Order effects
For group 1, the supplement period followed the diet
period. Many of these participants declined to return to
their baseline diets at the end of the period, despite the
study requirement that they do so. Thirty percent (N=6)
of these participants reported eating meat or fish less
than once a month or not at all during the washout and
the entire supplement period. An additional 2 partici-
pants reported avoiding meat and fish for at least the
4-week washout period.
Because of this incomplete cross-over, although clinical
characteristics of the two groups were not significantly dif-
ferent at baseline (Table 1), some were significantly differ-
ent at the start of the respective supplement periods (week
0 for group 2, week 20 for group 1). Body weight, VAS,
and headache intensity changed in group 1 during the diet
period and did not return to baseline levels during the
washout period (Additional file 1: Table S3).
A subanalysis of the headache data examining only the
first 16 weeks of the study was therefore conducted to
Table 4 Diet effects on clinical measures, study completers only
Diet period Supplement period Effect Size p
valueeBaseline 16 weeks Change Baseline 16 weeks Change
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Body weight (kg) (N=36)f 75.0 (18.7) 71.1 (17.3) −3.9 (3.8)a 73 (17.7) 72.9 (18.1) 0.0 (2.6) −3.9 (4.6) <0.001
BMI (N=36) 26.9 (5.7) 25.5 (5.2) −1.4 (1.4)a 26.2 (5.4) 26.2 (5.6) 0.0 (1.0) −1.4 (1.6) <0.001
Total cholesterol (N=35)g 185.9 (36.8) 169.3 (35.5) −16.5 (32.8)c 181.2 (31.7) 181.3 (36.4) 0.1 (25.4) −16.7 (41.5) 0.02
HDL (N=36) 60.9 (16.5) 54.6 (15.0) −6.3 (16.1)d 60.9 (14.7) 60.4 (14.8) −0.6 (10.4) −5.7 (19.9) 0.09
LDL (N=35) 105.5 (32.1) 94.2 (27.9) −11.3 (27)d 100.5 (26.2) 101.7 (30.9) 1.2 (20.4) −12.2 (33.6) 0.04
Ratio (N=35) 3.2 (1.0) 3.2 (0.9) 0.0 (0.9) 3.1 (0.7) 3.1 (0.8) 0.1 (0.7) 0.0 (1.2) 0.85
Triglycerides (N=35) 95.2 (46.4) 101.9 (43.5) 6.7 (56) 96.6 (36.6) 96.5 (55.0) −0.1 (53.2) 6.7 (83.7) 0.64
Log triglycerides (N=35) 1.93 (0.2) 1.97 (0.18) 0.04 (0.23) 1.95 (0.17) 1.94 (0.19) −0.01 (0.16) 0.05 (0.30) 0.30
VAS (cm) (N=35) 6.0 (2.7) 3.6 (3.0) −2.4 (3.2)a 4.7 (2.8) 4.1 (2.8) −0.6 (2.3) −1.8 (3.9) 0.01
Headache number (per wk) (N=35) 2.1 (1.4) 1.7 (1.9) −0.3 (1.2) 2.1 (2.0) 1.8 (2.2) −0.4 (0.9) 0.0 (1.3) 0.95
Headache intensity (N=33) 4.3 (1.8) 3.1 (1.8) −1.2 (1.7)b 3.6 (1.9) 3.2 (2.0) −0.4 (1.5) −0.8 (2.4) 0.07
Headache duration (N=33) 6.1 (4.1) 4.8 (3.6) −1.3 (2.7)c 4.5 (3.2) 4.4 (3.6) −0.1 (2.4) −1.2 (3.9) 0.08
Headache days (per wk) (N=35) 2.0 (1.4) 1.7 (1.6) −0.3 (1.1) 1.9 (1.6) 1.6 (1.6) −0.3 (0.7) 0.0 (1.2) 0.99
Number medicated (N= 35) 1.4 (1.1) 1.1 (1.6) −0.3 (1.6) 1.2 (1.2) 1.1 (1.1) −0.2 (0.7) −0.1 (1.7) 0.73
% medicated (N= 35) 65.2 (31.8) 41.3 (31.3) −23.8 (38.8)b 50.1 (32.3) 46.1 (33.6) −4.0 (22.5) −19.8 (49.7) 0.02
Abbreviations: BMI Body Mass Index, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, Ratio= Total cholesterol/HDL, VAS visual
analog pain scale, worst pain last 2 weeks, SD standard deviation.
ap<0.0001; bp<0.001; cp<0.01; dp<0.05.
ep values are from between-group T-tests.
fParticipants who attended the baseline and endpoint assessments for both treatments included here.
gCholesterol and triglycerides are reported in mg/dl.
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examine data free of the potentially confounding effects of
the incomplete crossover. This analysis showed significant
decreases in headache number, intensity, days, and num-
ber and percent medicated headaches in the diet group
(all p<0.05, Table 5). Modest improvements in headache
frequency, days, and number and percent medicated head-
aches were also observed in the supplement group. Al-
though between-group differences favored the diet group
in each case, these differences were significant only for
changes in headache intensity.
A multivariate analysis showed that VAS and headache
intensity at 16 weeks were significantly, positively associ-
ated with number of headaches at baseline. The effect of
the diet remained significant after adjustment.
Discussion
In a crossover design, a vegan diet was associated with
greater reductions in reported pain, as measured by
VAS, PGIC when compared with changes during the
supplement period. In addition, during the diet period,
significant changes were observed in headache intensity,
pain as measured by SF-36, as well as in body weight,
and total, LDL, and HDL cholesterol.
Previous studies have shown that a low-fat diet can
improve migraine pain [4]. In addition, elimination di-
ets have demonstrated effectiveness in several studies
[3,8,9]. We observed a smaller change in headache
days as compared to a previous study excluding IgG
antibody-eliciting foods [8]. This may be due to the
duration of the elimination diet intervention (6 weeks
as opposed to our 2–3 weeks), the extent of the dietary
restriction imposed on patients, or the methods of food
reintroduction.
Potential mechanisms
There are a number of possible mechanisms by which a
vegan and trigger-free diet could reduce pain. Evidence sug-
gests an involvement of neurogenic inflammation and
neurogenic vasodilation in migraine [20]. Many plant foods
are high in antioxidants and anti-inflammatory compounds.
In addition, a vegan diet excludes certain commonly re-
ported migraine triggers (ie, dairy products). Meat products
have been shown to have inflammatory properties [21,22],
and eliminating these might be expected to have an anti-
inflammatory effect. Some meats and cheeses are high in
tyramine, which has been linked to migraine [2].
The benefits of weight loss for migraine have been dem-
onstrated elsewhere [23,24]. Indeed, a recent paper on
weight loss and migraine showed symptom improvement
in a group following a low-calorie diet and a group follow-
ing a ketogenic very-low-calorie diet [25]. Therefore, it is
possible that the pain reducing effects of the vegan diet
may be, at least in part, due to weight reduction. In
addition, the possibility that lower blood pressure or hor-
monal changes [13], which commonly occur with plant-
based diets [13,26] may, in turn, favorably influence mi-
graine symptoms, cannot be ruled out.
In this study, some improvements in pain and clinical
measurements were observed during the supplement
period. Pain, as measured by the SF-36, improved, as did
headache number and headache days. These changes
may have been in part due to incomplete crossover for
group 1 (diet then supplement group), placebo, or sea-
sonal effects for both groups.
The study has several strengths. An advantage of diet-
ary interventions that include community volunteers
who are not confined or restricted is that the results
readily translate into real-life applications. This protocol
maximized dietary adherence by using group support
and frequent monitoring of reported dietary intake.
The study also has limitations. The self-reported na-
ture of pain is an inherent limitation of headache stud-
ies. Migraine triggers unrelated to diet, such as stress
and weather changes, cannot be controlled and may
have influenced the weekly headache diary data. Design-
ing a placebo control for diet studies is challenging. The
placebo supplement may not have been an ideal control
for the diet, since the process of a diet change is differ-
ent than the process of adding a daily supplement. How-
ever, it would not have been credible to ask control
participants to eliminate an arbitrary list of foods, so the
Figure 3 Change in pain. Number of participants in each treatment
reporting improvement (better; a little better, but no noticeable
change; somewhat better, but the change has not made a real and
worthwhile difference; moderately better, and a slight but noticeable
change; better, and a definite improvement that has made a real and
worthwhile difference) or no improvement (no change [or condition
has got worse]; almost the same, hardly any change at all; worse; much
worse) on the PGIC or change in pain questions.
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nutritional compound was deemed to be the most ap-
propriate control available.
The effects of the diet cannot be separated from the ef-
fects of the weekly classes. The SF-36 showed the diet was
associated with improved social functioning, and this may
have been an effect of the classes, of reduced pain, or both.
Although the intervention was intended to combine the
vegan diet with the elimination of additional foods that
may have been potential triggers, the individualized nature
of the elimination period meant that it was challenging to
separate the effects of the vegan diet per se from those of
the elimination period. In addition, some individuals had
not fully reintroduced all eliminated foods by study’s end.
Therefore, it is not possible to attribute the reported
changes in pain specifically to either the elimination or
vegan phase. A longer study, permitting a fuller elimination
and reintroduction period, could isolate those variables.
Many individuals were unwilling to return their previous
diets at the conclusion of the diet phase. Similarly, prior
crossover studies have reported that individuals trying
plant-based diets often refuse to abandon them, despite
protocol requirements [13,27]. While this observation sug-
gests some substantial benefit of the dietary intervention,
it created a methodologic problem in that the diets and
some outcome measures for group 1 participants were dif-
ferent from group 2 at the start of the supplement period
and that participants crossing into the supplement period
may continue to benefit from the previous dietary inter-
vention that they never fully abandoned. The net result of
these effects would be an apparent reduction in the ob-
served effectiveness of the dietary intervention.
Appropriately planned vegan diets are nutritionally ad-
equate for all life stages, and pose no additional risk for
patients [28]. In addition, a vegan diet presents advantages
in reduced risk for diabetes and heart disease, among
other conditions [29,30].
Conclusions
These results suggest potential value of a nutritional ap-
proach to migraine treatment. Further studies are needed
to enable dietary pain triggers to be isolated and to confirm
the usefulness of the vegan diet as compared to alternative
therapeutic diets. A longer trial, separating the effects of a
vegan intervention from a diet eliminating additional foods
would be helpful, if the considerable technical barriers to
such a study can be overcome.
Additional file
Additional file 1: Table S1. Change in pain. Table S2. 36-Item short
form survey for general health, intention-to-treat analysis. Table S3.
Outcomes analyzed for order effects on supplement period.
Table 5 Diet effects on clinical measures, analysis of first 16 weeks
Diet group (N=21) Supplement group (N=21) Effect size p
valuecBaseline 16 weeks Change Baseline 16 weeks Change
Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (SD) Mean (95% CI)
Body weight (kg)d 78.0 (22.6) 73.8 (22.1) −4.3 (4.5)a 75.7 (17.1) 75.3 (18.1) −0.4 (2.9) −3.9 (−6.2 to −1.5) 0.002
BMI 27.7 (6.4) 26.2 (6.3) −1.5 (1.7)a 27.5 (5.8) 27.3 (6.1) −0.2 (1.1) −1.4 (−2.2 to −0.5) 0.003
Total cholesterole 195.6 (42.5) 173.6 (48.9) −22.0 (41.7)b 186.9 (31.1) 185.6 (37.2) −1.3 (30.0) −20.7 (−43.6 to 2.1) 0.07
HDL 62.2 (17.6) 57.3 (17.1) −4.9 (19.1) 62.9 (12.9) 58.8 (12.1) −4.1 (9.5) −0.8 (−10.2 to 8.6) 0.86
LDL 111.0 (35.4) 95.5 (38.8) −15.5 (34.4) 104.9 (27) 107.2 (32.7) 2.4 (27.0) −17.8 (−37.3 to 1.7) 0.07
Ratio 3.3 (1.0) 3.1 (0.8) −0.1 (1.0) 3.1 (0.7) 3.3 (0.9) 0.2 (0.8) −0.3 (−0.9 to 0.3) 0.25
Triglycerides 107.8 (41.2) 101.1 (35.5) −6.7 (53.0) 95.5 (38.2) 98.1 (68.3) 2.6 (61.5) −9.3 (−45.6 to 27.1) 0.61
Log triglycerides 2.01 (0.15) 1.98 (0.16) −0.03 (0.21) 1.95 (0.18) 1.93 (0.23) −0.02 (0.16) 0.0 (−0.1 to 0.1) 0.85
VAS (cm) 6.1 (2.4) 3.0 (2.9) −3.1 (3.0)a 6.7 (1.9) 6.0 (2.0) −0.7 (2.4) −2.4 (−4.1 to −0.7) 0.007
Headache number (per wk) 2.1 (1.6) 1.6 (1.7) −0.5 (1.0)b 2.6 (2.1) 2.3 (2.4) −0.3 (1.0) −0.2 (−0.9 to 0.4) 0.46
Headache intensity 3.9 (1.1) 2.7 (1.8) −1.2 (1.8)b 4.5 (1.7) 4.5 (2) 0.0 (1.5) −1.2 (−2.3 to −0.1) 0.04
Headache duration, hrs 6.5 (3.3) 5.2 (4.4) −1.3 (3.0) 5.1 (3.5) 5.1 (2.8) 0.0 (2.3) −1.6 (−3.5 to 0.4) 0.15
Headache days (per wk) 2.1 (1.6) 1.6 (1.6) −0.4 (0.9)b 2.3 (1.2) 2.1 (1.5) −0.2 (0.9) −0.3 (−0.8 to 0.3) 0.38
Medicated headache number 1.6 (1.3) 1 (1.3) −0.6 (0.7)a 1.4 (0.8) 1.3 (0.9) −0.2 (0.7) −0.5 (−0.9 to 0.01) 0.06
% headaches medicated 61.8 (28.5) 44.3 (30.5) −17.5 (37.8)b 66.1 (29.6) 64.1 (32.5) −1.9 (24.1) −15.5 (−36.1 to 5) 0.13
Abbreviations: BMI Body Mass Index, HDL high-density lipoprotein cholesterol, LDL low-density lipoprotein cholesterol, Ratio= Total cholesterol/HDL, VAS visual
analog pain scale, worst pain last 2 weeks, SD standard deviation.
ap<0.001; bp<0.05, for within-group T-tests.
cp value is from between group T-test.
dFor specific N values, see Table 3.
eCholesterol and triglycerides are reported in mg/dl.
Bunner et al. The Journal of Headache and Pain 2014, 15:69 Page 8 of 9
http://www.thejournalofheadacheandpain.com/content/15/1/69
Abbreviations
BMI: Body mass index; HDL-cholesterol: High-density lipoprotein cholesterol;
LDL-cholesterol: Low-density lipoprotein cholesterol; IgG: Immunoglobulin G;
PGIC: Patient’s global impression of change; SD: Standard deviation;
SF-36: Rand Short Form 36; VAS: Visual analog pain scale.
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